Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

Date publication

avril 2019

Journal

JAMA oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BIBEAU Frédéric

Tous les auteurs :
Cohen R, Hain E, Buhard O, Guilloux A, Bardier A, Kaci R, Bertheau P, Renaud F, Bibeau F, Fléjou JF, André T, Svrcek M, Duval A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30452494

Résumé

Primary resistance to immune checkpoint inhibitors is observed in 10% to 40% of patients with metastatic colorectal cancer (mCRC) displaying microsatellite instability (MSI) or defective mismatch repair (dMMR).

Mots clés

Adult, Antineoplastic Agents, Immunological, therapeutic use, Colorectal Neoplasms, diagnosis, DNA Mismatch Repair, Diagnostic Errors, Drug Resistance, Neoplasm, Female, Humans, Male, Microsatellite Instability, Middle Aged, Predictive Value of Tests, Prospective Studies, Retrospective Studies

Référence

JAMA Oncol. 2019 Apr 1;5(4):551-555